21:44 , Dec 6, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

New Therapeutic Targets and Biomarkers: November 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November. Therapeutic targets are defined as any protein, gene or other molecule...
20:04 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML) Mouse and cell culture studies suggest inhibiting CPT1B could help treat CML in obese patients. In a mouse model of diet-induced obesity, levels of CPT1B on NK cells were higher...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
18:03 , Oct 25, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Bioinformatics screens A bioinformatics screen based on transcriptomic data sets could help identify new targets for approved drugs. The screen involved 3 steps: analyzing 2,052 genes from eight signaling pathways in data sets from...
18:17 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer, colorectal cancer Cell culture and mouse studies suggest inhibiting CPT1A alone or in combination with VEGF inhibition could help treat hepatocellular carcinoma and colorectal cancer. In a mouse colorectal cancer cell line...
23:23 , May 4, 2018 |  BC Extra  |  Preclinical News

PPAR agonist-induced fatty acid metabolism boosts tissue regeneration

Scientists at the Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology published a paper in Cell Stem Cell showing that fatty acid oxidation (FAO) induced by short-term fasting promotes tissue regeneration and repair,...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Perhexiline: Phase IIb started

Heart Metabolics began an open-label, U.S. Phase IIb trial to evaluate once-daily oral perhexiline in about 33 patients with moderate to severe heart failure and preserved left ventricular function. Patients will receive a starting dose...
07:00 , May 5, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carnitine palmitoyl transferase 1 (CPT1)

Endocrine/metabolic disease INDICATION: Cachexia Cell culture and mouse studies suggest inhibiting CPT1 could help treat cachexia in cancer patients. In a xenograft mouse model of kidney cancer-associated cachexia and a mouse model of lung cancer-associated...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carnitine palmitoyl transferase 1 (CPT1); CPT2; v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc)

Cancer INDICATION: Breast cancer Patient sample, mouse and cell studies suggest inhibiting CPT1 or CPT2 could help treat MYC-driven triple-negative breast cancer (TNBC). In TNBC patients, low tumor levels of acetyl-coenzyme A carboxylase β (...
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Targeted generic

Targeted generic Investors in Heart Metabolics Ltd. 's $20 million series A round think the company can use genetic testing to avoid the toxicities that have dogged perhexiline, a generic it is repurposing for hypertrophic...